Alkermes (ALKS) Interest Expenses (2010 - 2026)
Alkermes' (ALKS) quarterly Interest Expenses came in at $25.9 million in Q2 2026, up 24.09% quarter-over-quarter from $20.9 million in Q1 2026.
Analysis
Alkermes (ALKS) Interest Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Interest Expenses for 17 consecutive years, with $25.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Interest Expenses changed N/A year-over-year to $25.9 million in Q2 2026; TTM through Jun 2026 was $59.1 million, a 454.98% increase from a year earlier, with the FY2025 full-year figure at $12.3 million, down 45.62% from the prior year.
- Interest Expenses was $25.9 million for Q2 2026 at Alkermes, up from $20.9 million in the prior quarter.
- Over five years, Interest Expenses peaked at $25.9 million in Q2 2026 and troughed at $2.4 million in Q1 2022.
- A 5-year average of $7.8 million and a median of $6.0 million in 2024 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses plunged 40.81% in 2022 and surged 164.14% in 2025, its largest moves.
- Over 5 years, Interest Expenses stood at $4.8 million in 2022, then rose by 26.94% to $6.1 million in 2023, then decreased by 23.22% to $4.6 million in 2024, then soared by 164.14% to $12.3 million in 2025, then jumped by 111.17% to $25.9 million in 2026.
- The last three Interest Expenses figures came in at $25.9 million (Q2 2026), $20.9 million (Q1 2026), and $12.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | - |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 25.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.93 Mn |
| Mar 31, 2026 | 20.89 Mn |
| Dec 31, 2025 | 12.28 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | 6.00 Mn |
| Jun 30, 2024 | 5.95 Mn |
| Mar 31, 2024 | 5.98 Mn |
| Dec 31, 2023 | 6.05 Mn |
| Sep 30, 2023 | 6.01 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | 5.29 Mn |
| Dec 31, 2022 | 4.77 Mn |
| Sep 30, 2022 | 3.55 Mn |
| Jun 30, 2022 | 2.37 Mn |
| Mar 31, 2022 | 2.35 Mn |
| Dec 31, 2021 | 2.41 Mn |
| Sep 30, 2021 | 2.44 Mn |
| Jun 30, 2021 | 2.41 Mn |
| Mar 31, 2021 | 3.97 Mn |
| Dec 31, 2020 | 1.87 Mn |